Risankizumab

Definition

A humanized immunoglobulin G1 (IgG1) monoclonal antibody targeting the p19 subunit of human interleukin 23 (IL-23) cytokine, with anti-inflammatory activity. Upon administration, risankizumab targets and binds to the p19 subunit of human IL-23, inhibiting the interaction of IL-23 with the IL-23 receptor complex. This inhibits IL-23/IL-23 receptor-mediated signaling and inhibits the release of pro-inflammatory cytokines and chemokines. IL-23 plays an important role in the development, maintenance and activation of Th17 cells, which produce pro-inflammatory cytokines including IL-17A, IL-17F, and IL-22. It is upregulated in various inflammatory and autoimmune diseases.

Also known as ABBV-066, BI-655066, RISANKIZUMAB, Risankizumab-rzaa, Skyrizi — per NCIT

Also identified as

• ATC L04AC18 per RXNORM
• NCIT NCIT:C152227 per NCIT
• SCTID 787732000 per RXNORM
• SCTID 787746000 per RXNORM
• UNII 90ZX3Q3FR7 per RXNORM

Indications

Organ Effects

1 entry above is marked DERIVED: Atlas Médico inferred it by combining two sourced claims, and no source asserts this link directly. Treat it as a navigation aid, not as a clinical statement.